Pragmatism in Gout: How therapeutic choices can have multiple benefits Save

William James famously wrote in Pragmatism, “There can be no difference anywhere that doesn’t make a difference elsewhere.” Gout treatment offers a striking medical example of that idea. Drugs prescribed to calm flares or lower uric acid are designed with one primary goal in mind, yet many also produce meaningful effects beyond the joints. Some of those secondary effects are unwelcome; such as colchicine’s gastrointestinal intolerance, but others may prove surprisingly beneficial.

Broadly, gout medications fall into two groups: anti-inflammatory therapies that treat or prevent flares, and urate-lowering therapies that reduce the body’s uric acid burden and help dissolve monosodium urate crystals over time. Increasingly, research suggests that beyond the gout, these treatments positively affect the heart, blood vessels, kidneys, and skin.

Among urate-lowering agents, xanthine oxidase inhibitors such as allopurinol and febuxostat are the best studied. Their main purpose is to reduce urate production, but they may also offer kidney benefits. Multiple randomized and controlled studies have reported improvements in estimated glomerular filtration rate (eGFR) or reductions in adverse renal outcomes, particularly in patients with hyperuricemia and chronic kidney disease. Some smaller trials have also found modest reductions in blood pressure, raising the possibility that urate lowering, or possibly xanthine oxidase inhibition itself, improves vascular function. Allopurinol has another practical advantage: by lowering serum urate and influencing urinary chemistry, it can help reduce recurrent calcium oxalate stone formation in patients who get recurrent kidney stones.

The cardiovascular story is more complicated. Large trials have not consistently shown that urate-lowering therapy reduces major adverse cardiovascular events or overall mortality in the general population. Yet some gout-focused studies suggest that patients who achieve a serum urate below 6 mg/dL early in treatment may experience better long-term cardiovascular outcomes. Allopurinol has even shown anti-ischemic effects in chronic stable angina, with one study reporting improved exercise tolerance and delayed onset of angina and ST-segment depression at higher doses. These findings remain intriguing, even if they have not yet transformed routine practice.

Pegloticase, a recombinant uricase reserved for severe or refractory gout, may also have beneficial spillover effects. Post-hoc analyses of phase 3 trials have suggested that patients who responded to pegloticase experienced reductions in systolic, diastolic, and mean arterial blood pressure over several months. Small retrospective studies have also hinted that some patients with chronic kidney disease may see improvement in kidney function during treatment, especially when pegloticase is used successfully with immunomodulatory co-therapy. Whether these gains come from the drug itself or from profound urate reduction remains uncertain, but the association is difficult to ignore.

On the anti-inflammatory side, colchicine may be the most fascinating example of a gout drug with a life beyond gout. Long used for flare treatment and prophylaxis, colchicine has also shown benefit in cardiovascular disease, particularly in reducing recurrent ischemic events in selected patients with coronary disease. Its utility extends further: dermatologists and internists have long used colchicine in conditions such as leukocytoclastic vasculitis, Sweet syndrome, and recurrent aphthous stomatitis, where its ability to dampen neutrophil-driven inflammation becomes clinically useful.

Even NSAIDs, another common tool in gout care, have notable secondary effects. While their risks are well known, epidemiologic and mechanistic studies have suggested that certain NSAIDs, particularly those with increased COX-2 selectivity, may reduce the incidence of some cancers, with the strongest evidence in colorectal cancer reduction. Signals have also been reported in esophageal, gastric, breast, lung, prostate, and ovarian cancers, though these findings are less definitive and not sufficient to justify routine use for cancer prevention alone.

Taken together, gout therapies remind us that medications rarely act in isolation. A drug chosen for one purpose may influence several biological pathways at once, sometimes creating opportunities to improve more than a single disease. For clinicians, that broader view matters. In patients with gout, who often also carry burdens of kidney disease, hypertension, cardiovascular disease, and metabolic dysfunction, the ideal treatment may be one that does more than lower urate or stop a flare. Sometimes the best prescription is the one that makes a difference elsewhere, too.

References

1. Stamp LK, Chapman PT. Gout and its comorbidities: implications for therapy. Rheumatology (Oxford). 2013;52(1):34-44.
2. Tardif J-C, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497-2505.
3. Wang Y, Dalbeth N, Terkeltaub R, Zhang Y, Li X, Zeng C, Lei G, Wei J. Target Serum Urate Achievement and Chronic Kidney Disease Progression in Patients With Gout and Kidney Disease. JAMA Intern Med. 2025 Jan 1;185(1):74-82. doi: 10.1001/jamainternmed.2024.6212.
4. Johnson RJ, Choi HK, Yeo AE, Lipsky PE. Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout. Hypertension. 2019 Jul;74(1):95-101. doi: 10.1161/HYPERTENSIONAHA.119.12727.
5. Misiak M, Maciejowska A, Pałęga M, Burek R, Gołda A, Dworak M, Pawuła-Prgomet B, Forysiński K, Miłek T. The Effect of Anti-Inflammatory Drugs on the Incidence of Colorectal Cancer. Pharmaceutics. 2026 May 23;18(6):643. doi: 10.3390/pharmaceutics18060643.